New publication: Societal Preferences, Values and Priorities for Genomic Testing for Atrial Fibrillation: Evidence from Two Discrete Choice Experiments

What is the value of genomic testing for Atrial Fibrillation — from society’s perspective?

Genetics is increasingly associated with Atrial Fibrillation (AF) pathogenesis and has the potential to predict an individual’s risk of AF, its complications, or their responses to drug ablation therapies. Yet no evidence exists on how consumers weigh the risks and benefits of genomics in AF.

A new publication led by Ilias Goranitis and Cun(Lizzy) Liu, conducted two Discrete Choice Experiments to understand consumer preferences, values and priorities for genomic testing in AF.

Key findings:
(1) Participants demonstrated positive preferences for the health and non-health outcomes of genomics and had disutility of having to pay for testing.
(2) Cost is the major driver of preference for testing in AF. The two most valued benefits were clinical implications for monitoring personal cardiac complications other than AF and health implications for other family members.
(3) Society highly values the outcomes of genomics. Genomic testing was valued at AU$2900 for symptomatic patients and AU$2600 for at-risk relatives. The uptake of a publicly funded genomic testing for AF was predicted at 82%.

Read the full text here: https://rdcu.be/e3PJD